QURE · uniQure N.V. · Webcasts, Transcripts & Audio
$20.23
-0.07 (-0.34%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.42B
Shares
70.14M
Volume · Nov 19
1.16M
Avg daily vol (3M)
2.22M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
uniQure N.V. Webcasts
Earnings calls, investor updates, investor days and conferences for uniQure N.V. (QURE), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-11
uniQure N.V. (QURE) November 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-10
uniQure N.V. (QURE) November 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-04
uniQure N.V. (QURE) Q3 2026 Earnings Call Transcript
Confident tone
Confirmatory study execution
AMT-130 clinical efficacy
Regulatory progress
Revenue
$5.20M
▲ 40.4% YoY Diluted EPS
$-0.88
Gross margin
95.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-07-29
uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript
Confident tone
AMT-130 Huntington's disease regulatory progress
AMT-130 long-term clinical data
FDA confirmatory trial design
Revenue
$5.84M
▲ 11% YoY Diluted EPS
$-1.22
Gross margin
94.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-19
uniQure N.V. (QURE) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript
Balanced tone
AMT-130 in Huntington's disease
UK MHRA submission
UK commercial readiness and access
Revenue
$3.56M
▲ 127.3% YoY Diluted EPS
$-0.85
Gross margin
93.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-02
uniQure N.V. (QURE) Q4 2025 Earnings Call Transcript
Cautious tone
FDA feedback on regulatory path for AMT-130
External comparator from natural history data
Phase III sham-controlled study requirement
Revenue
$5.57M*
▲ 6.6% YoY Gross margin
92.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-10
uniQure N.V. (QURE) Q3 2025 Earnings Call Transcript
Cautious tone
FDA pre-BLA feedback and regulatory uncertainty
AMT-130 Huntington's disease pivotal data
AMT-162 SOD1 ALS program safety event
Revenue
$3.70M
▲ 61.8% YoY Diluted EPS
$-1.38
Gross margin
89.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript
Confident tone
AMT-130 pivotal data and regulatory progress
Huntington's disease competitive positioning
BLA readiness and manufacturing (PPQ/CMC)
Revenue
$5.26M
▼ 52.7% YoY Diluted EPS
$-0.69
Gross margin
87.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-06-02
uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript
Confident tone
AMT-130 Huntington's program and BLA pathway
Regulatory designations and FDA interactions
Pipeline expansion across other gene therapy programs
Revenue
$1.57M
▼ 81.5% YoY Diluted EPS
$-0.82
Gross margin
87.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
uniQure N.V. (QURE) Q2 2022 Earnings Call
Revenue
$497,000
▼ 99.9% YoY Diluted EPS
$-0.84
▼ 109.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-31
uniQure N.V. (QURE) Q2 2020 Earnings Call
Revenue
$1.53M
▼ 38% YoY Diluted EPS
$-0.96
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–12 of 12 webcasts
Key facts
CIK
1590560
CUSIP
N90064101
13F (30d)
268 filings
232 filers
Visit website
Investor relations